Capmatinib
| Evidence Level: L5 | Predicted Indications: 10 |
Table of Contents
Capmatinib: From Its Approved Oncology Use to Rheumatoid Arthritis
One-Sentence Summary
Capmatinib is a selective MET tyrosine kinase inhibitor, marketed in Singapore as an oral film-coated tablet (Tabrecta). The TxGNN model predicts it may be effective for rheumatoid arthritis, but this is currently a computational prediction only, with 0 clinical trials and 1 general review article that contains no RA-specific data.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not stated in the Singapore licence records compiled for this report |
| Predicted New Indication | Rheumatoid arthritis |
| TxGNN Prediction Score | 99.45% |
| Evidence Level | L5 |
| Singapore Market Status | ✓ Marketed |
| Number of Registrations | 2 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Capmatinib is a selective inhibitor of the MET receptor tyrosine kinase. Detailed mechanism-of-action data was not available in the data compiled for this report, so the following is based on general knowledge of the drug class.
MET signalling has been implicated in synovial inflammation and angiogenesis in rheumatoid arthritis. This gives the prediction a plausible biological rationale: blocking MET could, in theory, dampen processes that drive joint inflammation.
However, the only linked publication is a general review of FDA-approved kinase inhibitors, with no RA-specific data. The high TxGNN score reflects a computational prediction, not clinical support. The link between the drug's original use (a MET-driven cancer setting) and RA is therefore hypothetical at this stage.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 33513356 | 2021 | Review | Pharmacological Research | General update on FDA-approved small-molecule protein kinase inhibitors; contains no RA-specific data on capmatinib |
Singapore Market Information
| Authorization Number | Product Name | Dosage Form | Approved Indication |
|---|---|---|---|
| SIN16351P | TABRECTA FILM-COATED TABLET 200mg | Film-coated tablet | Not available |
| SIN16350P | TABRECTA FILM-COATED TABLET 150mg | Film-coated tablet | Not available |
Cytotoxicity
| Item | Content |
|---|---|
| Cytotoxicity Classification | Targeted therapy (MET tyrosine kinase inhibitor) |
| Myelosuppression Risk | Please refer to the package insert warnings and precautions |
| Emetogenicity Classification | Please refer to the package insert warnings and precautions |
| Monitoring Items | Please refer to the package insert warnings and precautions (typically including liver function tests and a blood count) |
| Handling Protection | Please refer to the package insert warnings and precautions |
Safety Considerations
- Drug Interactions: The interaction screen returned 100 potential interactions. Examples from the listed results:
- Major: dexamethasone, clarithromycin
- Moderate: metformin, empagliflozin, alosetron, loperamide, aprepitant, naltrexone, methylnaltrexone, naldemedine, metreleptin, glycerol phenylbutyrate
- Minor: proton pump inhibitors (omeprazole, esomeprazole, lansoprazole, dexlansoprazole, pantoprazole, rabeprazole), fidaxomicin, naloxegol
Common RA co-medications such as corticosteroids would need particular attention given the major interaction with dexamethasone.
Please refer to the package insert for warnings and contraindications.
Conclusion and Next Steps
Decision: Hold
Rationale: The prediction rests on a model score alone. There are no clinical trials, and the single linked publication is a general kinase inhibitor review with no RA data. The drug also has a large interaction burden, and its package-insert safety information has not yet been reviewed.
To proceed, the following is needed:
- Package insert warnings and contraindications from HSA (a blocking gap for safety screening)
- Approved indication text for the Singapore licences
- Detailed mechanism-of-action data
- Preclinical evidence (for example, in arthritis models) that MET inhibition by capmatinib reduces synovial inflammation
- A risk-benefit assessment of long-term kinase inhibition in a chronic, non-cancer population, including a review of the interaction profile with common RA therapies
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.